急性缺血性卒中的静脉溶栓治疗：从阿替普酶到替奈普酶。
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase.
作者信息
Yang Nan, Lee Hangil, Wu Chuanjie
机构信息
Department of Neurology, Xuanwu Hospital, Capital Medical University, Beijing, China.
Department of Neurosurgery, Wayne State University School of Medicine, Detroit, MI, USA.
出版信息
Brain Circ. 2023 Jun 30;9(2):61-63. doi: 10.4103/bc.bc_70_22. eCollection 2023 Apr-Jun.
Abstract
Stroke is one of the primary causes of morbidity and death worldwide. While intravenous (IV) thrombolysis with alteplase has been widely proven to be beneficial for acute ischemic stroke patients, it still has many limitations. Tenecteplase, a revised version of alteplase, is a potential alternative IV thrombolytic agent that has benefits over alteplase. The aim of this mini-review is to summarize the advancements in IV thrombolysis for severe ischemic stroke, specifically the development and transition from alteplase to tenecteplase.
摘要
中风是全球发病和死亡的主要原因之一。虽然静脉注射阿替普酶进行溶栓已被广泛证明对急性缺血性中风患者有益，但它仍有许多局限性。替奈普酶是阿替普酶的改良版，是一种潜在的静脉溶栓替代药物，比阿替普酶更具优势。这篇小型综述的目的是总结重症缺血性中风静脉溶栓的进展，特别是从阿替普酶到替奈普酶的发展和转变。
相似文献
1
Intravenous thrombolysis for acute ischemic stroke: From alteplase to tenecteplase.
Brain Circ. 2023 Jun 30;9(2):61-63. doi: 10.4103/bc.bc_70_22. eCollection 2023 Apr-Jun.
2
Using Tenecteplase for Acute Ischemic Stroke: What Is the Hold Up?
West J Emerg Med. 2020 Feb 24;21(2):199-202. doi: 10.5811/westjem.2020.1.45279.
3
Tenecteplase versus alteplase for stroke thrombolysis evaluation (TASTE): A multicentre, prospective, randomized, open-label, blinded-endpoint, controlled phase III non-inferiority trial protocol.
Int J Stroke. 2023 Jul;18(6):751-756. doi: 10.1177/17474930231154390. Epub 2023 Feb 2.
4
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29.
5
Tenecteplase versus Alteplase for the Management of Acute Ischemic Stroke in a Low-income Country-Nepal: Cost, Efficacy, and Safety.
Cureus. 2018 Feb 9;10(2):e2178. doi: 10.7759/cureus.2178.
6
Tenecteplase vs. alteplase for acute ischemic stroke: a systematic review.
Int J Emerg Med. 2022 Jan 4;15(1):1. doi: 10.1186/s12245-021-00399-w.
7
Intravenous Thrombolysis With Tenecteplase in Patients With Large Vessel Occlusions: Systematic Review and Meta-Analysis.
Stroke. 2021 Jan;52(1):308-312. doi: 10.1161/STROKEAHA.120.030220. Epub 2020 Dec 4.
8
Outcomes with IV tenecteplase and IV alteplase for acute ischemic stroke with or without thrombectomy in real-world settings in the United States.
J Stroke Cerebrovasc Dis. 2023 Feb;32(2):106898. doi: 10.1016/j.jstrokecerebrovasdis.2022.106898. Epub 2022 Dec 6.
9
Alteplase versus tenecteplase for thrombolysis after ischaemic stroke (ATTEST): a phase 2, randomised, open-label, blinded endpoint study.
Lancet Neurol. 2015 Apr;14(4):368-76. doi: 10.1016/S1474-4422(15)70017-7. Epub 2015 Feb 26.
10
Implementation of a Tenecteplase Protocol for Treatment of Acute Ischemic Stroke in a Health System.
Innov Pharm. 2024 Mar 18;15(1). doi: 10.24926/iip.v15i1.5801. eCollection 2024.
引用本文的文献
1
Molecular targets of neuroplasticity in ischemic stroke: insights from GEO database, single-cell analysis and immune infiltration analysis.
Front Aging Neurosci. 2025 Jul 25;17:1561282. doi: 10.3389/fnagi.2025.1561282. eCollection 2025.
2
Prediction of outcomes following intravenous thrombolysis in patients with acute ischemic stroke using serum UCH-L1, S100β, and NSE: a multicenter prospective cohort study employing machine learning methods.
Ther Adv Neurol Disord. 2025 Jun 10;18:17562864251342429. doi: 10.1177/17562864251342429. eCollection 2025.
3
A matters arising: discussion on urokinase dosing and individualized treatment strategies in the TRUST trial.
BMC Med. 2025 May 28;23(1):309. doi: 10.1186/s12916-025-04151-6.
4
Clinical outcomes of endovascular therapy in acute basilar artery occlusion with low pc-ASPECTS : Outcomes in ABAO with low pc-ASPECTS.
J Neurol. 2025 May 13;272(6):395. doi: 10.1007/s00415-025-13144-7.
5
Mitigating Early Phosphatidylserine Exposure in a Tmem30a-Dependent Way Ameliorates Neuronal Damages After Ischemic Stroke.
MedComm (2020). 2025 Mar 18;6(4):e70140. doi: 10.1002/mco2.70140. eCollection 2025 Apr.
6
Endothelial Cells and the Blood-Brain Barrier: Critical Determinants of Ineffective Reperfusion in Stroke.
Eur J Neurosci. 2025 Feb;61(3):e16663. doi: 10.1111/ejn.16663.
7
Intra-Arterial Tenecteplase Following Endovascular Reperfusion for Large Vessel Occlusion Acute Ischemic Stroke: The POST-TNK Randomized Clinical Trial.
JAMA. 2025 Feb 18;333(7):579-588. doi: 10.1001/jama.2024.23466.
8
Exosomes in Central Nervous System Diseases: A Comprehensive Review of Emerging Research and Clinical Frontiers.
Biomolecules. 2024 Nov 27;14(12):1519. doi: 10.3390/biom14121519.
9
Adjunctive PCSK9 Inhibitor Evolocumab in the Prevention of Early Neurological Deterioration in Non-cardiogenic Acute Ischemic Stroke: A Multicenter, Prospective, Randomized, Open-Label, Clinical Trial.
CNS Drugs. 2025 Feb;39(2):197-208. doi: 10.1007/s40263-024-01145-5. Epub 2025 Jan 5.
10
Electroacupuncture Protects Against Cerebral Ischemia-Reperfusion Injury: Reducing Inflammatory Response and Cell Pyroptosis by Inhibiting P2X7/NLRP3/GSDMD Pathway.
Neuropsychiatr Dis Treat. 2024 Nov 27;20:2335-2346. doi: 10.2147/NDT.S485884. eCollection 2024.
本文引用的文献
1
Intravenous tenecteplase compared with alteplase for acute ischaemic stroke in Canada (AcT): a pragmatic, multicentre, open-label, registry-linked, randomised, controlled, non-inferiority trial.
Lancet. 2022 Jul 16;400(10347):161-169. doi: 10.1016/S0140-6736(22)01054-6. Epub 2022 Jun 29.
2
Comparison of tenecteplase with alteplase for the early treatment of ischaemic stroke in the Melbourne Mobile Stroke Unit (TASTE-A): a phase 2, randomised, open-label trial.
Lancet Neurol. 2022 Jun;21(6):520-527. doi: 10.1016/S1474-4422(22)00171-5. Epub 2022 May 4.
3
Tenecteplase versus alteplase for the management of acute ischaemic stroke in Norway (NOR-TEST 2, part A): a phase 3, randomised, open-label, blinded endpoint, non-inferiority trial.
Lancet Neurol. 2022 Jun;21(6):511-519. doi: 10.1016/S1474-4422(22)00124-7. Epub 2022 May 4.
4
Off-Label Use of Tenecteplase for the Treatment of Acute Ischemic Stroke: A Systematic Review and Meta-analysis.
JAMA Netw Open. 2022 Mar 1;5(3):e224506. doi: 10.1001/jamanetworkopen.2022.4506.
5
Protection of multiple ischemic organs by controlled reperfusion.
Brain Circ. 2021 Dec 21;7(4):241-246. doi: 10.4103/bc.bc_59_21. eCollection 2021 Oct-Dec.
6
Timing is everything: Exercise therapy and remote ischemic conditioning for acute ischemic stroke patients.
Brain Circ. 2021 Aug 27;7(3):178-186. doi: 10.4103/bc.bc_35_21. eCollection 2021 Jul-Sep.
7
Tenecteplase for thrombolysis in stroke patients: Systematic review with meta-analysis.
Am J Emerg Med. 2021 Apr;42:31-37. doi: 10.1016/j.ajem.2020.12.026. Epub 2020 Dec 24.
8
Effect of Intravenous Tenecteplase Dose on Cerebral Reperfusion Before Thrombectomy in Patients With Large Vessel Occlusion Ischemic Stroke: The EXTEND-IA TNK Part 2 Randomized Clinical Trial.
JAMA. 2020 Apr 7;323(13):1257-1265. doi: 10.1001/jama.2020.1511.
9
Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update to the 2018 Guidelines for the Early Management of Acute Ischemic Stroke: A Guideline for Healthcare Professionals From the American Heart Association/American Stroke Association.
Stroke. 2019 Dec;50(12):e344-e418. doi: 10.1161/STR.0000000000000211. Epub 2019 Oct 30.
10
Tenecteplase versus alteplase for management of acute ischaemic stroke (NOR-TEST): a phase 3, randomised, open-label, blinded endpoint trial.
Lancet Neurol. 2017 Oct;16(10):781-788. doi: 10.1016/S1474-4422(17)30253-3. Epub 2017 Aug 2.
Zotero 插件